Targeting specific cells in the brain with nanomedicines for CNS therapies
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Treatment of Central Nervous System (CNS) disorders still remains a major clinical challenge. The Blood-brain-barrier (BBB), known as the major hindrance, greatly limits therapeutics penetration into the brain. Moreover, even though some therapeutics can cross BBB based on their intrinsic properties or via the use of proper nanoscale delivery vehicles, their therapeutic efficacy is still often limited without the specific uptake of drugs by the cancer or disease-associated cells. As more studies have started to elucidate the pathological roles of major cells in the CNS (for example, microglia, neurons, and astrocytes) for different disorders, nanomedicines that can enable targeting of specific cells in these diseases may provide great potential to boost efficacy. In this review, we aim to briefly cover the pathological roles of endothelial cells, microglia, tumor-associated microglia/macrophage, neurons, astrocytes, and glioma in CNS disorders and to highlight the recent advances in nanomedicines that can target specific disease-associated cells. Furthermore, we summarized some strategies employed in nanomedicine to achieve specific cell targeting or to enhance the drug neuroprotective effects in the CNS. The specific targeting at the cellular level by nanotherapy can be a more precise and effective means not only to enhance the drug availability but also to reduce side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Astrocytes: Biology and pathology
Sofroniew, M. V., & Vinters, H. V. (2010) · Acta Neuropathologica · doi:10.1007/s00401-009-0619-8 · Cited by 5,196 · cited 1×
“They participate in the metabolism of amino acids, nutrients, and ions in the brain, communication with neurons and BBB endothelium, as well as the modulation of excitatory synaptic transmission [51, 52].”
BackgroundStructure and function of the blood–brain barrier
Abbott, N. J., Patabendige, A. A. K., Dolman, D. E. M., Yusof, S. R., & Begley, D. J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.030 · Cited by 5,185 · cited 5×
“molecules that provides essential nutrients to the brain, ii) effluxing waste products, and iii) regulating homeostasis in the brain [4].”
BackgroundInfluentialDelivery of siRNA to the mouse brain by systemic injection of targeted exosomes
Alvarez-Erviti, L., Seow, Y., Yin, H., Betts, C., Lakhal, S., & Wood, M. J. A. (2011) · Nature Biotechnology · doi:10.1038/nbt.1807 · Cited by 4,930 · cited 2×
“Further studies have demonstrated that systemic delivery of siRNA using RVG peptide modified exosomes result in gene knockdown in neurons, microglia, oligodendrocytes [128].”
BackgroundMethodMicroglia-mediated neurotoxicity: uncovering the molecular mechanisms
Block, M. L., Zecca, L., & Hong, J.-S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2038 · Cited by 4,110 · cited 1×
“This cascade not only causes neuron damages, but also initiates microglia activation, which often exacerbates the injury as discussed previously [59].”
BackgroundTumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
Microglia: Active sensor and versatile effector cells in the normal and pathologic brain
Hanisch, U.-K., & Kettenmann, H. (2007) · Nature Neuroscience · doi:10.1038/nn1997 · Cited by 3,676 · cited 9×
“Microglial cells serve as the major resident immune cells in the CNS where they constantly monitor their surroundings and act as the mediator in innate immunity for early control of infections [19, 20].”
BackgroundInfluentialKettenmann, H., Hanisch, U.-K., Noda, M., & Verkhratsky, A. (2011) · Physiological Reviews · doi:10.1152/physrev.00011.2010 · Cited by 3,547 · cited 9×
“Microglial cells serve as the major resident immune cells in the CNS where they constantly monitor their surroundings and act as the mediator in innate immunity for early control of infections [19, 20].”
BackgroundInfluentialThe Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280 · cited 1×
“1 BBB Dysfunction—Dysfunction of BBB endothelial cells is an important feature in many CNS pathologies [12].”
BackgroundThe blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798
The blood-brain barrier/neurovascular unit in health and disease
Hawkins, B. T., & Davis, T. P. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.2.4 · Cited by 2,661
Drug Transport across the Blood–Brain Barrier
Pardridge, W. M. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.126 · Cited by 1,994
The Science of Stroke: Mechanisms in Search of Treatments
Moskowitz, M. A., Lo, E. H., & Iadecola, C. (2010) · Neuron · doi:10.1016/j.neuron.2010.07.002 · Cited by 1,930
Neuroinflammation and M2 Microglia: The Good, the Bad, and the Inflamed
Cherry, J. D., Olschowka, J. A., & O’Banion, M. K. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-98 · Cited by 1,748 · cited 4×
“This process generally starts from an initial microglia activation, which further develops into increased inflammation and glial activation when M2 responses occur and fail to exert their neuroprotective roles [26].”
BackgroundResultInfluentialMicroglia in neurodegenerative disease
Perry, V. H., Nicoll, J. A. R., & Holmes, C. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.17 · Cited by 1,543 · cited 1×
“In these instances, microglia respond to stimuli, such as aggregation of Aβ in AD and α-synuclein in PD, motor neuronal death in ALS, or signals from infiltrating lymphocytes in MS; and further produce more NO, ROS, proinflammatory cytokines (such as TNF-α, IL-1β, IL-6) that eventually cause progressive injury to othe…”
BackgroundTransvascular delivery of small interfering RNA to the central nervous system
Kumar, P., Wu, H., McBride, J. L., Jung, K.-E., Hee Kim, M., Davidson, B. L., Kyung Lee, S., Shankar, P., & Manjunath, N. (2007) · Nature · doi:10.1038/nature05901 · Cited by 1,246
Transferrin receptor on endothelium of brain capillaries
Jefferies, W. A., Brandon, M. R., Hunt, S. V., Williams, A. F., Gatter, K. C., & Mason, D. Y. (1984) · Nature · doi:10.1038/312162a0 · Cited by 1,061 · cited 1×
“On the other hand, internalization of substances can also occur by receptor-mediated transcytosis when ligands interact with their respective endothelial membrane receptors, such as transferrin receptor (TfR), melanotransferrin receptor (MTfR), lactoferrin (LfR), or LDL-receptor-related proteins [8-11].”
BackgroundTikka, T., Fiebich, B. L., Goldsteins, G., Keinänen, R., & Koistinaho, J. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-08-02580.2001 · Cited by 958 · cited 12×
“Some pro-inflammatory cytokines (such as TNF-α, IL-1β) can also activate astrocytes to induce over-production of ROS and NO that exacerbate the injury.”
BackgroundInfluentialSelective Ablation of Proliferating Microglial Cells Exacerbates Ischemic Injury in the Brain
Lalancette-Hébert, M., Gowing, G., Simard, A., Weng, Y. C., & Kriz, J. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.5360-06.2007 · Cited by 874
Possible involvement of the M2 anti‐inflammatory macrophage phenotype in growth of human gliomas
Komohara, Y., Ohnishi, K., Kuratsu, J., & Takeya, M. (2008) · The Journal of Pathology · doi:10.1002/path.2370 · Cited by 738 · cited 1×
“Although TAMs may polarize to M1 phenotype to give rise to proinflammatory effects (for initiating the clearance of potential hazards in CNS), their inflammatory functions are often suppressed in glioma pathology [23, 43-46].”
BackgroundBlood–brain barrier dysfunction in parkinsonian midbrain in vivo
Kortekaas, R., Leenders, K. L., van Oostrom, J. C. H., Vaalburg, W., Bart, J., Willemsen, A. T. M., & Hendrikse, N. H. (2005) · Annals of Neurology · doi:10.1002/ana.20369 · Cited by 733
The brain tumor microenvironment
Charles, N. A., Holland, E. C., Gilbertson, R., Glass, R., & Kettenmann, H. (2011) · Glia · doi:10.1002/glia.21136 · Cited by 718
Cirrito, J. R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25247 · Cited by 660
Nance, E. A., Woodworth, G. F., Sailor, K. A., Shih, T.-Y., Xu, Q., Swaminathan, G., Xiang, D., Eberhart, C., & Hanes, J. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003594 · Cited by 649 · cited 1×
“In addition to the widely-acknowledged barriers such as the BBB [148] and the extracellular space of brain parenchyma (both known for preventing nanoparticles from reaching the targeting site), [149] there are a few additional factors that need to be considered during the translation of cell-targeting nanomedicine.”
BackgroundNiewoehner, J., Bohrmann, B., Collin, L., Urich, E., Sade, H., Maier, P., Rueger, P., Stracke, J. O., Lau, W., Tissot, A. C., et al. (2014) · Neuron · doi:10.1016/j.neuron.2013.10.061 · Cited by 622
Drug delivery to the central nervous system by polymeric nanoparticles: What do we know?
Kreuter, J. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.008 · Cited by 554
Huitinga, I., van Rooijen, N., de Groot, C. J., Uitdehaag, B. M., & Dijkstra, C. D. (1990) · The Journal of experimental medicine · doi:10.1084/jem.172.4.1025 · Cited by 506 · cited 2×
“For example, clodronate encapsulated in liposome was shown to successfully eliminate circulating macrophages but not the resident microglia, with concomitant reduction in clinical signs of experimental autoimmune encephalomyelitis (EAE) [96, 97].”
BackgroundWeinstein, J. S., Varallyay, C. G., Dosa, E., Gahramanov, S., Hamilton, B., Rooney, W. D., Muldoon, L. L., & Neuwelt, E. A. (2010) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2009.192 · Cited by 500 · cited 1×
“Many nanoparticle platforms have been designed to target microglia/macrophage so that they can bring the therapeutics to the diseased regions for the treatments of neurodegenerative disorders (such as AD/PD) or glioblastoma [89-102].”
BackgroundModulation of immune response by head injury
Morganti-Kossmann, M. C., Satgunaseelan, L., Bye, N., & Kossmann, T. (2007) · Injury · doi:10.1016/j.injury.2007.10.005 · Cited by 412
Michelucci, A., Heurtaux, T., Grandbarbe, L., Morga, E., & Heuschling, P. (2009) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2009.02.003 · Cited by 411
Regulation of Microglial Proliferation during Chronic Neurodegeneration
Gómez-Nicola, D., Fransen, N. L., Suzzi, S., & Perry, V. H. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.4440-12.2013 · Cited by 407
Targeting Astrocytes Ameliorates Neurologic Changes in a Mouse Model of Alzheimer's Disease
Furman, J. L., Sama, D. M., Gant, J. C., Beckett, T. L., Murphy, M. P., Bachstetter, A. D., Van Eldik, L. J., & Norris, C. M. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.2323-12.2012 · Cited by 313
Phase I Study of GRN1005 in Recurrent Malignant Glioma
Drappatz, J., Brenner, A., Wong, E. T., Eichler, A., Schiff, D., Groves, M. D., Mikkelsen, T., Rosenfeld, S., Sarantopoulos, J., Meyers, C. A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2481 · Cited by 190
Cohen, Z. R., Ramishetti, S., Peshes-Yaloz, N., Goldsmith, M., Wohl, A., Zibly, Z., & Peer, D. (2015) · ACS Nano · doi:10.1021/nn506248s · Cited by 182
Lipid Nanoparticle Delivery of siRNA to Silence Neuronal Gene Expression in the Brain
Rungta, R. L., Choi, H. B., Lin, P. J., Ko, R. W., Ashby, D., Nair, J., Manoharan, M., Cullis, P. R., & MacVicar, B. A. (2013) · Molecular Therapy—Nucleic Acids · doi:10.1038/mtna.2013.65 · Cited by 165 · cited 2×
“In some studies, neuronspecific targeting was achieved by taking advantage of the vehicle’s intrinsic ability to interact with neurons (Table 3) [122, 123].”
BackgroundEngineered lentiviral vector targeting astrocytes In vivo
Colin, A., Faideau, M., Dufour, N., Auregan, G., Hassig, R., Andrieu, T., Brouillet, E., Hantraye, P., Bonvento, G., & Déglon, N. (2009) · Glia · doi:10.1002/glia.20795 · Cited by 158
Yemisci, M., Caban, S., Gursoy-Ozdemir, Y., Lule, S., Novoa-Carballal, R., Riguera, R., Fernandez-Megia, E., Andrieux, K., Couvreur, P., Capan, Y., et al. (2015) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2014.220 · Cited by 118
Infiltrating Macrophages Are Key to the Development of Seizures following Virus Infection
Cusick, M. F., Libbey, J. E., Patel, D. C., Doty, D. J., & Fujinami, R. S. (2013) · Journal of Virology · doi:10.1128/jvi.02747-12 · Cited by 112
Macrophages Offer A Paradigm Switch for CNS Delivery of Therapeutic Proteins
Klyachko, N. L., Haney, M. J., Zhao, Y., Manickam, D. S., Mahajan, V., Suresh, P., Hingtgen, S. D., Mosley, R. L., Gendelman, H. E., Kabanov, A. V., et al. (2014) · Nanomedicine · doi:10.2217/nnm.13.115 · Cited by 92
Montagne, A., Gauberti, M., Macrez, R., Jullienne, A., Briens, A., Raynaud, J.-S., Louin, G., Buisson, A., Haelewyn, B., Docagne, F., et al. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.07.018 · Cited by 70 · cited 1×
“Grafting VCAM-1 targeting peptides to ultrasmall superparamagnetic iron oxide allowed the designed nanoparticles being used for the detection of cerebrovascular cell activation in multiple models (such as stroke and ischemia), serving as a valuable strategy for non-invasive and quantitative evaluation for neuroinflamm…”
Method
Cited by
Function and therapeutic value of astrocytes in neurological diseases
Lee, H.-G., Wheeler, M. A., & Quintana, F. J. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00390-x · Cited by 662
Microglia in the Retina: Roles in Development, Maturity, and Disease
Silverman, S. M., & Wong, W. T. (2018) · Annual Review of Vision Science · doi:10.1146/annurev-vision-091517-034425 · Cited by 346
Li, J., & Kataoka, K. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.0c09029 · Cited by 281
Microglia-targeting nanotherapeutics for neurodegenerative diseases
Zhao, N., Francis, N. L., Calvelli, H. R., & Moghe, P. V. (2020) · APL Bioengineering · doi:10.1063/5.0013178 · Cited by 104
Clinical translation of nanomedicines for brain diseases: Current challenges and future directions
Wang, G., Wang, N., Xia, X., Ismail, M., & Shi, B. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114426 · Cited by 33
Metadata
- Authors
- Zhang, F., Lin, Y.-A., Kannan, S., & Kannan, R. M.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2016-10
- Volume
- 240
- Pages
- 212-226
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2192157366
- Cited by
- 110
- References
- 39
- FWCI
- 1.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.